AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 116 min read$SWAG

Stran & Company, Inc. (SWAG): Results of Operations and Financial Condition

Stran & Company, Inc. (SWAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030143401ex99-1.htm PRESS RELEASE DATED AUGUST 11, 2026 Exhibit 99.1 Stran & Company Reports $33.4 Million in Revenue and $0.6 Million in EBITDA for the Second Quarter of 2026 Conference Call to be Held Wednesday, August 12, 2026 at 10:00 a.m. Eastern Time Quincy, MA

Original reporting
SEC EDGAR 8-K
Published Aug 11, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$SWAG
Bullish
medium confidence
Mentioned
$SWAG
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SWAGBullishMed
01

Why it matters

The disclosure updates investors on profitability (gross profit, EBITDA), segment trends (Stran vs SLS), and capital allocation (repurchase activity), setting expectations for the Aug 12 call.

02

Market read

Fresh quarterly and year-to-date financials plus a stated new contract and resumed share repurchases create a tradable catalyst ahead of the scheduled conference call.

03

What to watch

Traders may overemphasize first-half strength; the key swing factor is whether SLS gross margin expansion and operating income durability persist beyond order timing effects.

Relevance 7/10Novelty 7/10Timing: after-hours filing today, conference call scheduled Aug 12 at 10:00 a.m. ET

Background

This is an SEC 8-K (Item 2.02) with Exhibit 99.1 press release covering Stran’s Q2 and first-half 2026 financial results and business update.

Company-level read

Ticker impact

$SWAGBullishMedium confidence
Context

Stran reported Q2 2026 results with $33.4M revenue (+2.4% YoY) and $0.6M EBITDA, plus a new enterprise contract and resumed buybacks.

Expected impact

Moderate positive bias into/after the Aug 12 conference call, with focus on margin trajectory and whether SLS variability stabilizes.

Evidence & confidence

Revenue and gross profit rose in both quarter and first-half, EBITDA improved, and management highlighted a new contract and resumed repurchases; however, net income and EBITDA for the quarter are modest and SLS revenue timing variability remains a caveat.

Market effects

Sector

Adds datapoint on outsourced marketing/promotional products demand and profitability leverage, but no direct sector-wide catalyst is disclosed.

Regional

No specific regional macro or supply-chain shock is mentioned.

Global

Primarily company-specific; no international regulatory or macro linkage is provided.

Counterpoint

What could challenge this read

Quarterly EBITDA declined versus the prior-year quarter ($0.6M vs $0.9M), and SLS revenue timing variability could mask weaker underlying demand.

Key entities

  • company
    Stran & Company, Inc.

    Outsourced marketing solutions provider reporting Q2 and first-half 2026 results and business update in an 8-K.

  • business_segment
    Stran Loyalty Solutions, LLC (SLS)

    Segment highlighted for improving gross profit and operating income, with noted revenue timing variability.

  • executive
    Andy Shape

    CEO quoted on first-half performance and business progress.

Read at source← All news

Related articles

AUG 11
$MLYSMedAI 8/10

Why is Mineralys Therapeutics stock sliding today?

Investing.com reports Mineralys Therapeutics (MLYS) shares fell 4.9% in after-hours after posting a Q2 2026 per-share loss of $2.85 versus a $2.63 analyst consensus. The loss followed a rise in operating costs, including $221.4 million R&D and a $200 million upfront payment to Tanabe for lorundrostat royalty buyout. FDA PDUFA is Dec. 22, 2026.

investing.com4 min
AUG 11
$IAUMed

i-80 Gold Q2 Earnings Call Highlights

i-80 Gold (TSE:IAU) reported Q2 cash of about $465M (down from $514M in Q1) and Q2 revenue just over $24M. Gold production was ~11,100 oz with ~5,300 oz sold. Management said Granite Creek resource work supports a feasibility study expected in Q3 2026, while Archimedes feasibility is delayed to mid-2027; Lone Tree refurbishment remains on track for first gold by end-2027.

yahoo.com6 min
AUG 11
$INUVMed

Inuvo, Inc. (INUV): Results of Operations and Financial Condition

Inuvo, Inc. (INUV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 inuvo_ex991.htm PRESS RELEASE inuvo_ex991.htm EXHIBIT 99.1 Inuvo Reports Second Quarter 2026 Results Audience Modeling Revenue Grows 19% as Company Streamlines Legacy Search and Strengthens Capital Position Management to host conference call at 4:15 PM ET, Tuesday, Augu

SEC EDGAR 8-K6 min
AUG 11
$SNALMedAI 9/10

Why is Snail stock plummeting today?

Investing.com reports Snail Inc. (SNAL) shares fell 30.9% in after-hours to $3.17 after Q2 2026 results missed expectations. Revenue was $19.7M, down 11.3% YoY and below a ~$29M consensus. Bookings fell 19.6% to $21.8M and net loss was $3.0M. The sell-off was company-specific.

investing.com4 min
AUG 11
$RDVTMed

Red Violet, Inc. (RDVT): Results of Operations and Financial Condition

Red Violet, Inc. (RDVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rdvt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 red violet Reports Second Quarter 2026 Financial Results Record Revenue of $26.7 Million, an Increase of 23%; Record Cash Flow from Operations of $10.6 Million BOCA RATON, Fla. – August 10, 2026 – Red Violet, Inc. (NASDAQ: RD

SEC EDGAR 8-K4 min
AUG 11
$ABSIHighAI 9/10

Why is Absci stock tumbling today?

Absci Corp shares fell 16.6% in after-hours after reporting Q2 2026 results. According to the company, revenue was $0.3M versus about $1.01M expected and down from $0.6M a year earlier. The per-share loss was $0.21 versus a $0.19 expected loss, with a $33.2M net loss. CEO cited Phase 1 HEADLINE trial interim data, but investors focused on the financial miss.

investing.com3 min